Clinical studies of reversal of drug resistance based on glutathione

Chemico-Biological Interactions

Volumn 111-112, Issue , 1998, Pages 213-224

  Calvert, Paula ^a,b   Yao, Kang Shen ^a,b   Hamilton, Thomas C ^a,b   O'Dwyer, Peter J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Electrophiles; Glutathione; Homeostasis

Indexed keywords

ALKYLATING AGENT; BUTHIONINE SULFOXIMINE; CISPLATIN; GLUTATHIONE; MELPHALAN; PLATINUM DERIVATIVE;

BONE MARROW TOXICITY; CANCER; CANCER RESISTANCE; CELL METABOLISM; CLINICAL TRIAL; DRUG ACTIVITY; HUMAN; MONONUCLEAR CELL; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; THROMBOCYTOPENIA;

EID: 18544399201     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00008-8     Document Type: Article

References (38)

1. Meister A. Selective modification of glutathione metabolism. Science. 220:1983;472-477.
2. Arrick B.A., Nathan C.F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 44:1984;4224-4232.
3. Godwin A.K., Meister A., O'Dwyer P.J. et al. High resistance to cisplatin in human ovarian cancer cells lines is associated with marked increased of glutathione synthesis. Proc. Natl. Acad. Sci. USA. 89:1992;3070-3074.
4. Yao K.-S., Johnson S.W., Godwin A.K., Ozols R.F., O'Dwyer P.J., Hamilton T.C. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res. 55:1995;4367-4374.
5. Yao K.-S., Godwin A.K., Ozols R.F. et al. Variable baseline γ-glutamylcysteine synthetase mhNA expression in peripheral mononuclear cells of cancer patients and its induction by buthionine sulfoximine treatment. Cancer Res. 53:1993;3663-3666.
6. O'Dwyer P.J., Yao K.-S., Ford P. et al. Effects of hypoxia upon detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. Cancer Res. 54:1994;3082-3087.
7. Yao K.S., Hageboutros A., Ford P., O'Dwyer P.J. Involvement of activator protein-1 and nuclear factor-kB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Mol. Pharmacol. 51:1997;422-430.
8. O'Dwyer P.J., Johnson S.W., Khater C., Krueger A., Matsumoto Y., Hamilton T.C., Yao K.S. The chemopreventive agent oltipraz stimulates repair of damaged DNA. Cancer Res. 57:1997;1050-1053.
9. Wang X., Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 map kinase. Science. 272:1996;1347-1349.
10. Paul S., Breuninger L.M., Tew K.D., Shen H., Kruh G.D. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc. Natl. Acad. Sci. USA. 93(14):1996;6929-6934.
11. Cole S.P.C., Bharchwaj G., Gerach J.H., Mackie Z.E., Grant C.E., Alugust K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Overexpression of a transport gene in a multidrug resistant human lung cancer cell line. Science. 258:1992;1650-1654.
12. Lautier D., Canitrot Y., Deeley R.G., Cole S.P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol. 52(7):1996;967-977.
13. Alper T. The modification of damage cause by primary ionization of biological targets. Radiat. Res. 5:1956;573-586.
14. Bump E.A., Yu N.Y., Brown J.M. Radiosensitization of hypoxic tumor cells by depletion of intracellular glutathione. Science. 217:1982;544-545.
15. Somfai-Relle S., Suzukake K., Vistica D.T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem. Pharmacol. 33:1984;485-490.
16. Suzukake K., Petro B.J., Vistica D.T. Dechlorination of L-phenylalanine mustard by sensistive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol. 32:1983;16-167.
17. Hamilton T.C., Winkler M.A., Louis K.G. et al. Augmentation of Adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol. 34:1985;2583-2586.
18. Ozols R.F., Louis K.G., Plowman J. et al. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol. 36:1987;147-153.
19. Louie K.G., Behrens B.S., Kinsella T.J. et al. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res. 45:1985;2110-2115.
20. Mistry P., Kelland L.R., Sidhar A.S. et al. The relationship between, glutathione S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer. 64:1991;215-220.
21. Britten R.A., Green J.A., Warenius H.M. Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor giopsies following exposure to alkylating agents. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;527-531.
22. Bailey H., Gipp J.J., Ripple M. et al. Increase in g-glutamycysteine synthetase activity and steady-state messenger RNA levels in melphanan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res. 52:1992;5115-5118.
23. Karin M., Liu Z., Zardi E. AP-1 function and regulations. Curr. Opin. Cell Biol. 9:1997;240-246.
24. Griffith O.W. Mechanism of action, metabolism and toxicity of buthionine sulfoximineand its higher homologues, potent inhibitors of glutathione synthesis. J. Biol. Chem. 257:1982;13704-13712.
25. Bailey H.H., Mulcahy R.T., Tutsch K.D., Arzoomanian R.Z., Alberti D., Tombes M.B., Wilding G., Pomplun M., Spriggs D.R. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin. Oncol. 12(1):1994;194-205.
26. O'Dwyer P.J., Hamilton T.C., LaCreta F.P. et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 14:1996;249-256.
27. O'Dwyer P.J., Hamilton T.C., Young R.C. et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results. J. Natl. Cancer Inst. 84:1992;264-267.
28. F.P. LaCreta, J.M. Brennan, T.C. Hamilton et al. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. Drug Metab. Distribution, in press.
29. O'Dwyer P.J., Szarka C., Gallo J.M., Yao K.-S., Hum S.T., Green F., Halbherr T., Brennan J., Pfeiffer G.R., Frucht H., Goosenberg R.B., Engstrom P.F., Clapper M. Modulation of detoxicating enzyme gene expression in patients receiving the chemopreventive dithiolethione oltipraz. J. Clin. Invest. 98:1996;1210-1217.
30. Bailey H.H., Wilding G., Tutsch R.D. et al. A phase I trial of L-S,R-buthionine sulfoxi-mine (BSO) given as a 24-48 h continuous infusion (CI) with iv melphalan (L-PAM). Proc. Am. Soc. Clin. Oncol. 13:1994;1351.
31. Suzukake K., Petro B.J., Vistica D.T. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem. Pharmacol. 31:1982;121-124.
32. Ball C.R., Connors T.A., Double J.A. et al. Comparison of nitrogen mustard sensitive and resistant Yoshida sarcomas. Int. J. Cancer. 1:1966;319-327.
33. Begleiter A., Grover J., Froese E. Membrane transport, sulfhydryl levels and DNA crosslinking in Chinese hamster ovary cell mutants sensitive and resistant to melphalan. Biochem. Pharmacol. 32:1983;293-300.
34. Suzukake K., Petro B.J., Vistica D.T. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol. 32:1983;165-167.
35. Hamilton T.C., Winker M.A., Louie K.G. et al. Augmentation of Adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol. 34:1985;2583-2586.
36. Ozols R.F., Louie K.G., Plowman J. et al. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol. 36:1987;147-153.
37. O'Dwyer P.J., Hamilton T.C., LaCreta F.P. et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 14:1996;249-256.
38. Bailey H.H., Mulcahy R.T., Tutsch K.D. et al. Phase I trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin. Oncol. 12:1994;194-205.